Member Info for The_Paladin

Peterkel.

SYME is the same as any other small cap investment. The investor purchases an equity holding, presumably based on extensive research beforehand?

It doesn’t have a maturity date like a savings bond! There are risks involved. The investor could reap many multiples of their investment; alternatively, in extreme cases they could lose it all.

SYME is a very complex endeavour. If it attracts the right financial backers, it could prove to be very profitable for us all.

I actually sold some of my holding recently. I may buy back within my ISA should the price drop by 10-15% from here.

Have a good day everyone.

TommyD_19.

It is obvious that again you are replying to one of my contributions without bothering to read it fully. There was no offence or derision, as you put it, intended towards FruitsnVeg, whose comments I value, and have provided me with several pieces of useful information. I merely made a humorous reference to FruitsnVeg’s recent contribution, when he stated (perhaps with tongue in cheek?) that there were only five individuals contributing to this board, under multiple aliases. I was attempting a humorous reference to that comment, and not to the contributor.

You have made it perfectly obvious, time and time again, that you have taken a personal dislike to a number of contributors on this forum, presumably linked to their comments about the company? That is fine by me. I am perfectly capable of responding in kind. However, please do not make an inaccurate response to any of my comments again, without bothering to read, and comprehend what has been written.

It may be better if we agree to mutually filter each other’s comments. I have already filtered your contributions, and suggest that you do the same with mine. That way you won’t need to take offence on anyone’s behalf in future, when it is clear that no offence was offered or intended.

There is no point whatsoever in these extraneous contributors (unless they are part of Fruitsnveg’s famous five that is?) listing these recent articles from sources, who deliberately set out to sensationalise the issues to attract readership.

Synairgen has, for a long time, summarised the issue on its website;

“* Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.

* There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.”

The issue, as I see it is to achieve regulatory approval for SNG001 as soon as it is realisically possible. To begin with, we need suitable P2 results as a means of convincing a major bio-pharmaceutical entity to entering a P3 partnership agreement with us.

There may be other routes towards regulatory approval but the latter seems to be the one that this forum’s investors are talking about.

Frankly, the recent hyperbolic posting here is a total waste of time IMHO.

Have a great weekend everyone.

There is no information to substantiate yesterday's welcomed share price rise. The ongoing emergence of viral infections causing temporary crises in various countries worldwide cannot be linked to Synairgen in any shape or form. The company is leak proof, and we cannot assume that there are any deals being discussed until news of them is communicated by RNS.

I was surprised to see the excellent Respiratory Futures documentary mentioned as this first appeared exactly one year ago. Likewise, any speculation involving TFG Holdings is groundless. Further, the peer review of the COPD data reiterates information we already knew, although it offers reassurance from a LTI perspective.

My position remains the same, that being to continue to hold, and wait for any news of the forthcoming P2s. This will be announced in an RNS, when the company has the information available to investors - sometime during H1 2024. Should there be another development meanwhile, it will be released in a similar fashion. There is little point in speculating too much about yesterday's rise until we receive relevant information that is substantiated by Synairgen. AS a LTI, whose patience has been severely tested over the last 21 months, I hope we won't have to wait too much longer.

Have a good day everyone.

An interesting article, which maintains that the surge of respiratory illness amidst the young was not unexpected. Moreover, it did not arise from a new virus, but from a combination of viruses and bacterial infections that the Chinese were shielded from under extreme lockdown conditions. We have to trust the statements from the Chinese Medical Authorities and the WHO on this.

However, it is another striking example of the need for a broad spectrum antiviral treatment like Synairgen in the toolkit to reduce the extreme symptoms that some patients experience in severe multi viral outbreaks such as this. These outbreaks are never going to disappear. There will always be a need for appropriate treatments to alleviate the symptoms which cause suffering and death in extreme cases amidst the World’s population.

Severe viral respiratory illness is ever present from various sources, and to varying degrees. Even the context of the historical novel that I am currently reading has the high death rate from influenza in Germany in 1919 in its factually true context. We just cannot get away from it!

https://www.cdc.gov/respiratory-viruses/data-research/dashboard/illness-severity.html

All Synairgen investors continue to wait for an update concerning the planned P2s. We know that a successful outcome to these imminent (hopefully?) trials will place SNG001 on track towards becoming part of the treatment given to particular patients suffering from the severe symptoms of a myriad of respiratory illnesses. My hope is that the data that eventually emerges from these trials will be of sufficient quality to attract a partnership deal during H1 2024, or soon thereafter. All this remains to be seen for the time being. Keep the faith! Ignore the unnecessary cynicism that is too often present on online fora.

The past is behind us, and many of us lost out on a good profit in aspiring towards that multi billion MCap, and the associated gain for all investors.

I was totally wrong on that score, but am now positively focussed on the forthcoming company-led P2s. In particular, on the potential outcome should they be successful?

Like Doc.Daneeka, I found the reference to pipettes in a job description amusing. More 1970s than AI-led preliminary research. I suspect that the advertisement was heavily based on an old draft from way back when? It looks to have been cobbled together, although if it succeeds in recruiting the right individual, it will have served its purpose.

On that subject, it is high time for Synairgen to update their website. They will want to present themselves as an aspirational company with an innovative and unique solution to contribute as a treatment for a multiplicity of respiratory viruses. They really should ensure that all their information is kept up to date. Potential partners will no doubt be scanning their documentation carefully before making an approach, if they haven’t already done so?

Agreed MisterGreen. These forums should be for reasoned comment and discussion, and for sharing information. Unfortunately some narcissistic individuals seem to treat them as a social media space to post about themselves and their alleged accomplishments.

Like you I have been waiting for nearly two years for a significant piece of news. Let us all hope that 2024 turns out to be a transformational year for SYME, and with it our invested capital. It would be useful to see more focus from Mr. Zamboni on this company, until there is a significant change in its fortunes. His attention seems to spread over a number of different projects, when this company has so many unresolved issues, which probably need his full attention.

Rather than re- read all the company’s information since the most recent strategy change, I have been re-examining the time line of significant Synairgen events over the last five years. Further, I have considered the correlation between these time markers with the share price graph over the same period.

The share price was at the current level prior to the start of the P2 trial, which launched the progress to the P3 Sprinter trial. I have no clue whether, as before, we will see more investor interest when the forthcoming P2 trials’ protocols, and their launch dates are announced?

These trials can’t start soon enough for me. I agree though with others who state that it is imperative to have the best possible strategy, underpinned by strong scientific evidence, in place prior to the launch of the P2s. Perhaps we will learn more this side of Christmas?

Have a good day everyone.

No IQ-AI investor would begrudge Mr. Brown any additional profit via the CLN route if that is his interim strategy?

To my thinking, it doesn’t explain why the share price continues to remain at the lower end of the stock’s trading range over recent months?

From the company’s perspective, there has only been promising news, which ought to have propelled the share price to a higher level IMHO? I remain optimistic about our potential progress to a significantly higher share price than at present. I now view the situation as a case of ‘when’ rather than ‘if’.

Have a good day everyone.

The lack of activity on this board is similar to that on the forum of one of my key investments. In both cases, a strategy is in motion, and investors continue to wait for an update on its progress. In both cases, investors will need to be extremely patient. Progress, if any, in both cases, is occurring in what seems like a glacial time scale.

At least this board is not being subjected by the attentions of an advfn contributor, whose aims appears to be an attempt to deflect investors out of SYME. His persistence is questionable, especially as he is also endorsing another investment, which on the surface is a non starter.

I have learned not to trust extreme negativity, and especially not extreme positivity from bulletin board contributors . The latter lead to heavy paper losses nearly two years ago. I am still nowhere near recovering from that position, although my current plan is a long term holding strategy.

Have a good day everyone.

In the absence of an update, short term speculative investors will move their capital elsewhere. This has happened before, and seems to be the case here at present.

This was always a long term investment. It will remain so until the company’s software engineers are able to refine their algorithms to achieve a robust and fully functional system, and AZ and his associates have the necessary financial backing in place.

This is a highly complex endeavour. If successful, investors will no doubt achieve a considerable uptick to their original invested capital.

Have a good weekend everyone.

Below is an extract from Phillips’ planned discussion at the RSNA Conference to be held in Chicago at the end of this month. It will be interesting to follow up on what emerges from this discussion.

https://www.rsna.org/annual-meeting?gad_source=1&gclid=EAIaIQobChMIoKOs_czIggMVnIBQBh2pugA9EAAYAyAAEgLAB_D_BwE

AI is an important feature to IB’s clinical solutions. Its success can but add value to my IQAI investment.

Have a good day everyone.

“How clinical AI is changing Radiology for good.

Artificial intelligence (AI) continues to be a central focus in addressing the future of radiology, patient care and healthcare system operations. Every day new AI-enabled technologies and solutions emerge, and we are already seeing the effect they are having on the practice of radiology. In this expert panel discussion, we’ll discuss the top trends in AI that are already providing high clinical impact today, as well as the importance of ethical, responsible and sustainable AI to support patient care and clinical practice in the future.”

Recently, when the lancet peer review of the results of our US NIH-led Activ-2 P2 trial appeared on the LinkedIn Synairgen pages, there was one notable thumbs up among the usual people. This was Richard May, Senior Director, Head Translational Discovery Sciences, Infectious Diseases, Janssen.

This is fingertip grasping of straw ends on my part, but it was good to see his positive affirmation of that study.

Yet more of putting the cart in front of the horse by the CEO and Board. This can only send out the wrong message to potential investors.

This comes at a time when we continue to wait for information concerning the P2 trials’ protocols, and the commencement of those trials. Sometime in H1 2024 is all we have been told regarding the current strategy.

Had the recent unnecessary (IMHO) hires and the unnecessary hires from 2021 purchased a personal stake in Synairgen, it would have sent out the right message to investors. As thing stand, the CEO continues to spend investor capital, with not the slightest hint of any future capital generation. His unnecessary recruitment has added approx £2m to the wage bill of our top heavy tiny bio -pharmaceutical company.

I am beginning to question the CEO’s ability to lead the company over a make or break year? Unfortunately, it is too late to dispense with his leadership. Perhaps that should have happened in March 2022?

There wasn't a significant rise. Today's closing price was 6.57p (+ 1.08%).

A company cannot proceed with trialling without a foundation of scientific evidence. The evidence presented by Synairgen prior to the completion of their Sars Cov- 2 Phase 3 trial (slides 6 - 19 below) was overwhelming.

https://synairgen.ams3.digitaloceanspaces.com/21-09-30-synairgen-interim-results-presentation-final.pdf

Decisions were taken prior to the trial's completion on the assumption that it would be successful. These decisions continue to add extensively (est. £1-2m p.a.) to the company's cash burn today. Similar decisions have been taken recently. Presumably, these have been taken on the assumption that the forthcoming company- led P2 trials will be successful, and will lead to the necessary BP partnership to take our treatment forward to further trialling and eventual commercialisation?

All LTI investors will hope that the company will succeed and that the value of our shareholdings will be significantly augmented as a result. News from Synairgen concerning pre-trial progress and the dates of the P2 trials' commencement cannot come soon enough for me. All LTIs do need reassurance from the company as quickly as possible.

I keep receiving messages from Alessandro Zamboni on X (twitter). Unfortunately, all these are in Italian, and are exclusively concerned with a Crypto training initiative. Is this his next venture? It would be reassuring if he focussed his attention exclusively on Syme. Most of his previous Syme deadlines have long expired. Excuses about the state of the World don't hold water when he seems to be extending his interest to other ventures.

"New-found optimism in the share from 1st Nov? Of course there is."

No there isn't. There is still the same optimism, as existed when we received our last update in late April 2023.

On April 27, when we discovered that there were no "concrete" proposals for BP partnerships or Platform Trials, and we were told that:

" Additionally, we plan to assess SNG001 in immunocompromised patients who are particularly vulnerable to respiratory viral infections, ventilated patients with confirmed viral pneumonia, and also those who appear unable to clear virus and become long term "shedders" and mutation hosts.

The plan will start with a series of focused, investigator-led/Synairgen-sponsored studies, using existing resources, which are intended to lead towards a Phase 3 registrational programme. Preparation is underway for these focused trials to initiate in H2 2023."

Since then, there have been resignations from the Board and Leadership Team, two Senior Appointments to the Leadership Team, and a peer- review of the Activ-2 trial was published. All the data that was collected during previous trials has by now been extensively analysed and presented at significant venues.

However, there is no new found optimism. That can only follow a reset to the share price, which is currently hovering around 12- month lows. Our optimism, such as it is, rests on progress with the "new" plan, which was issued over 6 months ago. I look forward to an update, which will probably emerge sometime during H1 2024?

An interesting article, and observed timeline gunto. It could well all come together for Synairgen via a synergetic collaborative P3 trial as you suggest.

We have been kept in the dark for 20 months, and the announcement of the trial protocols, followed by the start of Synairgen's P2 trials themselves cannot come soon enough as far as I am concerned.

I remain cautiously optimistic about the company's long term future, although the CEO and BOD have offered little to investors. We were given an amorphous strategy for well over a year, until the current plan emerged at the last AGM. There hasn't been a great deal of information since then. The Market concurs, and has contined to value the company solely on the dwindling residual investor capital from the P3 Sprinter trial for well over a year.

I understand that the process towards preliminary P2 trials is laborious and time consuming. I hope for all our sakes that the company is eventually able to deliver a successful outcome to the latter initiative, for the benefit of all very patient LTIs in particular.

Have a good day everyone.